In a recent study of a mouse Lewis lung cancer cell model, the pGC-1 α activator bezafibrate maintained the cell survival and function of CTLs by increasing expression of fatty acid oxidation-related genes (PGC-1α, CPT1A) in CTLs, and synergistic therapy with an anti-PD-L1 antibody enhanced its tumour-killing ability [134]. The gene discussed is CPT1A; the disease is neoplasm.